These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 10220313)
61. Mutagenesis study of Asp-290 in cytochrome P450 2B11 using a fusion protein with rat NADPH-cytochrome P450 reductase. Harlow GR; Halpert JR Arch Biochem Biophys; 1996 Feb; 326(1):85-92. PubMed ID: 8579377 [TBL] [Abstract][Full Text] [Related]
62. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Marohnic CC; Panda SP; McCammon K; Rueff J; Masters BS; Kranendonk M Drug Metab Dispos; 2010 Feb; 38(2):332-40. PubMed ID: 19884324 [TBL] [Abstract][Full Text] [Related]
63. Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Sandhu P; Guo Z; Baba T; Martin MV; Tukey RH; Guengerich FP Arch Biochem Biophys; 1994 Feb; 309(1):168-77. PubMed ID: 8117105 [TBL] [Abstract][Full Text] [Related]
64. Expression of recombinant human cytochrome P450 1A2 in Escherichia coli bacterial mutagenicity tester strain. Chun YJ Arch Pharm Res; 1998 Jun; 21(3):305-9. PubMed ID: 9875448 [TBL] [Abstract][Full Text] [Related]
65. Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ. Lozano JJ; López-de-Briñas E; Centeno NB; Guigó R; Sanz F J Comput Aided Mol Des; 1997 Jul; 11(4):395-408. PubMed ID: 9334905 [TBL] [Abstract][Full Text] [Related]
66. Increased Phenacetin Oxidation upon the L382V Substitution in Cytochrome P450 1A2 is Associated with Altered Substrate Binding Orientation. Huang Q; Szklarz GD Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29799514 [TBL] [Abstract][Full Text] [Related]
67. Marked enhancement in the reductive dehalogenation of hexachloroethane by a Thr319Ala mutation of cytochrome P450 1A2. Yanagita K; Sagami I; Daff S; Shimizu T Biochem Biophys Res Commun; 1998 Aug; 249(3):678-82. PubMed ID: 9731196 [TBL] [Abstract][Full Text] [Related]
68. Effect of mutations at Lys250, Arg251, and Lys253 of cytochrome P450 1A2 on the catalytic activities and the bindings of bifunctional axial ligands. Krainev AG; Shimizu T; Hiroya K; Hatano M Arch Biochem Biophys; 1992 Oct; 298(1):198-203. PubMed ID: 1524428 [TBL] [Abstract][Full Text] [Related]
69. Use of heterologously-expressed cytochrome P450 and glutathione transferase enzymes in toxicity assays. Guengerich FP; Wheeler JB; Chun YJ; Kim D; Shimada T; Aryal P; Oda Y; Gillam EM Toxicology; 2002 Dec; 181-182():261-4. PubMed ID: 12505322 [TBL] [Abstract][Full Text] [Related]
70. Plasmid-mediated expression of the UmuDC mutagenesis proteins in an Escherichia coli strain engineered for human cytochrome P450 1A2-catalyzed activation of aromatic amines. Josephy PD; Evans DH; Williamson V; Henry T; Guengerich FP Mutat Res; 1999 Oct; 429(2):199-208. PubMed ID: 10526205 [TBL] [Abstract][Full Text] [Related]
71. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Iwata H; Fujita K; Kushida H; Suzuki A; Konno Y; Nakamura K; Fujino A; Kamataki T Biochem Pharmacol; 1998 Apr; 55(8):1315-25. PubMed ID: 9719488 [TBL] [Abstract][Full Text] [Related]
72. [Modeling of a three-dimensional structure of cytochrome P-450 1A2 and search for its new ligands]. Belkina NV; Skvortsov VS; Ivanov AS; Archakov AI Vopr Med Khim; 1998; 44(5):464-73. PubMed ID: 9916262 [TBL] [Abstract][Full Text] [Related]
73. Co-expression of active human cytochrome P450 1A2 and cytochrome P450 reductase on the cell surface of Escherichia coli. Quehl P; Hollender J; Schüürmann J; Brossette T; Maas R; Jose J Microb Cell Fact; 2016 Feb; 15():26. PubMed ID: 26838175 [TBL] [Abstract][Full Text] [Related]
74. [Site-directed mutagenesis of Lac Z gene in Escherichia coli and the kinetic properties of the mutated enzymes]. Chu X; Bai Y; Yuan J Wei Sheng Wu Xue Bao; 1994 Jun; 34(3):206-12. PubMed ID: 7975556 [TBL] [Abstract][Full Text] [Related]
75. Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2. Cho US; Park EY; Dong MS; Park BS; Kim K; Kim KH Biochim Biophys Acta; 2003 May; 1648(1-2):195-202. PubMed ID: 12758162 [TBL] [Abstract][Full Text] [Related]
76. Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression. Palma BB; Silva E Sousa M; Vosmeer CR; Lastdrager J; Rueff J; Vermeulen NP; Kranendonk M Pharmacogenomics J; 2010 Dec; 10(6):478-88. PubMed ID: 20125119 [TBL] [Abstract][Full Text] [Related]
78. New applications of bacterial systems to problems in toxicology. Guengerich FP; Gillam EM; Shimada T Crit Rev Toxicol; 1996 Sep; 26(5):551-83. PubMed ID: 8891430 [TBL] [Abstract][Full Text] [Related]
79. Long-range effects of a peripheral mutation on the enzymatic activity of cytochrome P450 1A2. Zhang T; Liu LA; Lewis DF; Wei DQ J Chem Inf Model; 2011 Jun; 51(6):1336-46. PubMed ID: 21598960 [TBL] [Abstract][Full Text] [Related]
80. Conformational change of cytochrome P450 1A2 induced by phospholipids and detergents. Yun CH; Song M; Kim H J Biol Chem; 1997 Aug; 272(32):19725-30. PubMed ID: 9242629 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]